Clinical Trial Update: FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of FR901228 in patients with refractory stomach cancer or gastroesophageal junction cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Gastric Adenocarcinoma

Drugs mentioned

• FR901228 (romidepsin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Esophagus, Adenocarcinoma of the Stomach | Phase 2 | Status: TERMINATED